Drug Trial Radar · NCT06566079
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Dec 27, 2024
Primary completion
Aug 31, 2027
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- InSilico Medicine Hong Kong LimitedIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic mesothelioma or other Advanced solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection expansion part (Part 2).
Conditions
- Malignant Mesothelioma
- Metastatic Malignant Solid Tumor
- Advanced Solid Tumor
Interventions
ISM6331Drug
Dosage form: Capsule for oral administration. Frequency of administration: Once daily overall of treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicity (DLT).Time frame: Day 1 up to Day 31
- Incidence and severity of adverse events (AEs)Time frame: Approximately 12 months.
- Incidence of clinically significant abnormalities in laboratory values, vital signs, physical examination, and electrocardiogram (ECG) measurements.Time frame: Approximately 12 months.
- Recommended Phase 2 Dose (RP2D)Time frame: Approximately 40 months
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Sarah Cannon Research Institute at HealthONE
Denver, Colorado · Recruiting
The University of Chicago Medical Center - Duchossois Center for Advanced Medicine
Chicago, Illinois · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
NEXT Oncology - Austin
Austin, Texas · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Sun Yat-Sen University Cancer Center
Guangzhou, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.